Business Description
Protalix BioTherapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US74365A1016
Compare
Compare
Traded in other countries / regions
PLX.USAPBDA.GermanyPLX.Israel IPO Date
2007-03-12Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.58 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.68 | |||||
| Debt-to-EBITDA | 1.63 | |||||
| Interest Coverage | 4.43 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -3.02 | |||||
| Beneish M-Score | -0.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -35.6 | |||||
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.8 | |||||
| 3-Year FCF Growth Rate | 26.8 | |||||
| 3-Year Book Growth Rate | 65.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | -0.65 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.74 | |||||
| 9-Day RSI | 52.39 | |||||
| 14-Day RSI | 49.76 | |||||
| 6-1 Month Momentum % | -24.3 | |||||
| 12-1 Month Momentum % | 47.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.67 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 0.95 | |||||
| Days Inventory | 410.38 | |||||
| Days Sales Outstanding | 31.58 | |||||
| Days Payable | 101.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -53.6 | |||||
| Shareholder Yield % | 2.89 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.03 | |||||
| Operating Margin % | 21.34 | |||||
| Net Margin % | 16.69 | |||||
| FCF Margin % | -13.57 | |||||
| ROE % | 94.61 | |||||
| ROA % | 14.95 | |||||
| ROIC % | 43.7 | |||||
| ROC (Joel Greenblatt) % | 116.99 | |||||
| ROCE % | 39 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.2 | |||||
| Forward PE Ratio | 18.25 | |||||
| PE Ratio without NRI | 29.2 | |||||
| PS Ratio | 1.66 | |||||
| PB Ratio | 2.79 | |||||
| Price-to-Tangible-Book | 2.79 | |||||
| EV-to-EBIT | 6.17 | |||||
| EV-to-EBITDA | 5.72 | |||||
| EV-to-Revenue | 1.44 | |||||
| EV-to-Forward-Revenue | 1.82 | |||||
| EV-to-FCF | -10.6 | |||||
| Price-to-Graham-Number | 1.9 | |||||
| Price-to-Net-Current-Asset-Value | 4.56 | |||||
| Earnings Yield (Greenblatt) % | 16.21 | |||||
| FCF Yield % | -8.11 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:PLX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protalix BioTherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 63.625 | ||
| EPS (TTM) ($) | 0.05 | ||
| Beta | -0.21 | ||
| Volatility % | 65.14 | ||
| 14-Day RSI | 49.76 | ||
| 14-Day ATR ($) | 0.089426 | ||
| 20-Day SMA ($) | 1.436 | ||
| 12-1 Month Momentum % | 47.27 | ||
| 52-Week Range ($) | 1.09 - 3.55 | ||
| Shares Outstanding (Mil) | 72.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protalix BioTherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protalix BioTherapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Protalix BioTherapeutics Inc Frequently Asked Questions
What is Protalix BioTherapeutics Inc(PLX)'s stock price today?
The current price of PLX is $1.46. The 52 week high of PLX is $3.55 and 52 week low is $1.09.
When is next earnings date of Protalix BioTherapeutics Inc(PLX)?
The next earnings date of Protalix BioTherapeutics Inc(PLX) is 2024-02-27 Est..
Does Protalix BioTherapeutics Inc(PLX) pay dividends? If so, how much?
Protalix BioTherapeutics Inc(PLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers